Q1 2019 Richter Gedeon Vegyeszeti Gyar Nyrt Earnings Call Transcript
Good day and welcome to the Richter Announcement conference call. Today's conference is being recorded.
At this time, I would like to turn the conference over to Mr. Gabor Orban, CEO. Please go ahead, sir.
Thank you very much, and good morning, everyone. Thank you for joining us this morning. As usual, I'd like to begin by making a few introductory comments on this quarter's earnings report and then discuss the dynamics on the revenue side, on the cost side, the margins and the financial results, and then allow some time for you to ask questions.
I'd like to begin by sharing with you that the group's revenue increased on the year by close to EUR17 million up to EUR383 million, of which EUR307 million came from the pharma segment.
The EUR17 million change [mass] relatively or maybe even usually high number of -- large number of factors that affected this revenues. The most important being the increase in Vraylar royalty, which amounted to EUR12 million and the extra $25 million sales milestone that
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
